



## Review article

## Decoding the aging nexus: unravelling genetic networks and pharmacological strategies for lifespan extension and the methuselah paradox

Anamitra Goswami<sup>1</sup>, Nabanita Mukherjee<sup>2,3</sup>, Moumita Sil<sup>2</sup>, Ankita Ghosh<sup>2</sup>, Prashant Ratnaparkhi<sup>1</sup>,  
Arunava Goswami\*<sup>2</sup>, Igor Polikarpov<sup>4</sup>

<sup>1</sup>Department of Life Science & Biochemistry, St. Xavier's College, Mumbai, Maharashtra, India.

<sup>2</sup> Biological Sciences Division, Institute of National Importance, Indian Statistical Institute, Kolkata, West Bengal, India.

<sup>3</sup> Department of Zoology, Jangipur College, University of Kalyani, West Bengal, India

<sup>4</sup> University of São Paulo, São Carlos Institute of Physics, Department of Physics and Interdisciplinary Science, São Carlos, SP – Brazil.

**Corresponding author:** Arunava Goswami, ✉ srananisopananarunava@gmail.com, **Orcid Id:** <https://orcid.org/0000-0001-5799-0349>

Biological Sciences Division, Institute of National Importance, Indian Statistical Institute, Kolkata, West Bengal, India.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by-nc/4.0/>). See <https://jmpas.com/reprints-and-permissions> for full terms and conditions.


**Received - 28-10-2023, Revised - 02-12-2023, Accepted - 08-02-2024 (DD-MM-YYYY)**

### Refer This Article

Anamitra Goswami, Nabanita Mukherjee, Moumita Sil, Ankita Ghosh, Prashant Ratnaparkhi, Arunava Goswami, Igor Polikarpov, 2024. Decoding the aging nexus: unravelling genetic networks and pharmacological strategies for lifespan extension and the methuselah paradox. Journal of medical pharmaceutical and allied sciences, V 13 - I 1, Pages - 6372 – 6376. Doi: <https://doi.org/10.55522/jmpas.V13I1.6243>.

### ABSTRACT

We are all interested in knowing- whether genes and drugs can increase our life-span. As per Bible, Methuselah's lifespan lasted for a total of 969 years. Recent research has identified the Methuselah gene, a specific DNA segment that holds the potential to promote robust and healthy aging.



This discovery opens new avenues for the development of pharmaceutical interventions aimed at extending human lifespan. Aging, a complex process influenced by natural selection, has evolved over time, adapting to factors such as cellular senescence and genetic instability. Research on aging has extensively employed invertebrate models like cnidarians, worms, flies, and yeast. Utilizing genetic methodologies with these organisms has resulted in the identification of numerous aging genes. Remarkably, there is compelling evidence of evolutionary conservation within longevity pathways across diverse species, including mammals. In search of omic study, we would consider data from another set of experiments performed on Cnidarians and show that there has a great advanced on the 'biology of aging' in an indirect way. Cnidarians, like *Turritopsis dohrnii*, showcase "ontogeny reversal," reverting to earlier stages, thus achieving biological immortality through repeated rejuvenation after reproduction. Alternatively, compounds like resveratrol and rapamycin, have been identified as having the ability to decelerate aging in model organisms. However, as of now, only rapamycin has demonstrated an impact on longevity in experiments on mice. The opportunity to postpone human aging currently exists, whether through established groups of tiny molecules or numerous emerging alternatives. In this context, we explore the approaches to convert findings from age-related research into pharmaceuticals.

**Keywords:** Biological immortality, Genomic exploration, Invertebrate models, Anti-aging drugs, Aging mechanisms

## INTRODUCTION

Researchers have identified the Methuselah gene, a specific DNA fragment that grants individuals the potential for a robust and healthy old age. The methuselah gene mutation in *Drosophila melanogaster* extends lifespan by 35% and enhances stress resistance, potentially involving signal transduction pathways [1]. As creatures get older, the power of natural selection to influence their traits weakens, especially for qualities that matter before they have children. This means that harmful traits that only show up late in life don't get removed from the gene pool quickly [2]. As a result, the process of aging has changed over time by adjusting the characteristics associated with staying healthy as one gets older [3]. Additionally, aging has evolved by adapting to the factors that cause aging, such as cellular senescence or genetic instability. These factors can affect the capability of cells to transform into various cell types and their ability to regenerate [4]. Cnidarians have genes similar to more complex animals, showing how nature and aging are connected in fascinating ways. They share certain genomic structural characteristics and essential genes with bilaterians, shedding light on the intriguing interplay between evolutionary forces and the intricacies of aging and development [5-7]. Certain cnidarians display "ontogeny reversal," reverting to earlier stages, a phenomenon observed in *Turritopsis species*. The ground breaking research of Pascual-Torner et. al. (2022) showed that *Turritopsis dohrnii* uniquely achieves biological immortality by maintaining high rejuvenation capacity in post-reproduction. Studies also revealed the genomic sequencing of *T. dohrnii* and *Turritopsis rubra* (a species lacking rejuvenation). Comparative gene analysis, including DNA repair genes and aging, offers insights into *T. dohrnii's* extraordinary rejuvenation, emphasizing the need for whole-genome sequencing for comprehensive understanding [8-11].

The exploration of aging's intricacies traces back to Darwin's pondering, with initial theories proposing group selection. Evolutionary dynamics were shaped by limited life expectancy, largely

due to infectious diseases, childbirth, and malnutrition. Recent centuries witnessed unprecedented demographic shifts, with global life expectancy surpassing 80. Aging, a primary risk element for prevalent diseases, now confronts societies with an aging populace beset by chronic ailments. Research on lengthening health span emerges as a potential solution, but aligning aging interventions with prevention proves challenging. Regulatory hurdles, the gradual nature of aging, and unclear efficacy post-disease onset pose complex questions for the integration of anti-aging drugs into healthcare strategies.

In this overview, we briefly address advancements in the exploration of immortality-related genes before shifting our focus to small molecules influencing aging. Our discussion will delve into the detailed examination of the two extensively researched compounds, rapamycin and resveratrol.

### Unravelling the Molecular processes of *Turritopsis dohrnii's* Biological Immortality and Rejuvenation: Genomic, Transcriptomic, and Functional Insights

The study delves into the genomic and transcriptomic exploration of *Turritopsis dohrnii's* rejuvenation phenomenon, providing insights into endless vitality and challenging established aging paradigms. Pascual-Torner et al. (2022) present a comparative analysis of entire-genome assemblies between the non-immortal species *Turritopsis rubra* and *T. dohrnii*. The research uncovers genetic variants associated with key functions, including replication, telomere maintenance, DNA repair, redox regulation, stem cell dynamics, and cell-to-cell communication. During the life cycle reversal (LCR) procedure in *T. dohrnii*, there is a documented suppression of polycomb repressive complex 2 objectives and an activation of pluripotency-related targets, suggesting the involvement of these transcription factors in pluripotency induction. Another study focuses on oxidative stress responses and genomic stability in *T. rubra* and *T. dohrnii*, revealing genetic variations contributing to enhanced redox regulation and DNA repair mechanisms in *T. dohrnii*. Additional investigations explore variations in telomeric sequences,

shedding light on potential contributions to diminished telomere attrition and enhanced cellular adaptability [12-14]. The genetic insights into cellular adaptability and regeneration mechanisms highlight gene amplifications in *T. dohrnii* associated with apoptosis, neural system regulation, and microtubule function, providing valuable understanding of the species' extraordinary adaptability and regeneration capabilities [15-18]. Furthermore, the study on transcriptional regulation and epigenetic modifications reveals genetic variations affecting chromatin binding modulation and calcium binding sites, offering implications for cellular function and aging regulation [19-21]. The combined findings contribute significantly to unravelling the molecular intricacies underlying *Turritopsis dohrnii*'s pursuit of biological immortality and its unique capacity for rejuvenation [22-25].

### **Rapamycin: Unravelling a Journey from Easter Island to Aging Interventions**

The narrative of rapamycin unfolds from a 1960s Canadian scientific expedition to Easter Island, where a soil sample yielded a potent activity capable of killing eukaryotic cells. This activity was later attributed to the discovery of rapamycin, a small molecule produced by bacteria [26]. Since its identification, rapamycin has undergone extensive research, with clinical trials investigating its applications in various disease conditions. Notably, rapamycin and its derivatives, known as rapalogs, have received approval for several disease indications despite significant side effects [27, 28]. A major breakthrough in the field occurred with the identification of the Target of Rapamycin (TOR) kinase, revealing insights into TOR signalling and its association with longevity. Reduced TOR signalling, particularly TORC1 activity, has been connected to extended lifespan in yeast, worms, flies, and mice [29, 30]. In mouse aging studies, rapamycin demonstrated remarkable longevity benefits, extending lifespan in both males and females [31]. The drug also exhibited potential in delaying age-associated pathologies, including neurodegenerative diseases and cardiac hypertrophy [32, 33]. However, chronic administration raised concerns, as it failed to address certain phenotypes and, in some cases, accelerated specific age-related conditions. Despite challenges and side effects, rapamycin's potential to delay aging and delay age-related chronic diseases in humans remains a promising avenue, demonstrating proof-in-principle for interventions in the aging mechanisms.

### **Sirtuins, Resveratrol and Small Molecules: Deciphering Longevity Pathways in Yeast to Mice**

This passage delves into the intricate world of Sirtuins, a class of protein deacetylases, and their implications for longevity across various organisms [34]. Beginning with yeast, where Sirtuins, particularly Sir2, have been connected to enhanced replicative lifespan through mechanisms like suppressing rDNA recombination, the narrative extends to worms and flies, exploring controversial findings

on the impact of Sirtuin orthologs on aging [35]. In mice, the focus shifts to SIRT1 and resveratrol, uncovering tissue-specific effects and their potential roles in enhancing longevity [36, 37]. The section also delves into the controversial nature of resveratrol and Sirtuin Activating Compounds (STACs), detailing their in vitro and in vivo effects on SIRT1 activity [38-40]. Despite conflicting data on their ability to extend mouse lifespan, these small molecules open avenues for clinical applications. The passage highlights the complexity of unravelling Sirtuin functions, emphasizing the need for further studies to unlock the total spectrum of their roles in aging and potential clinical benefits.

### **Metformin and Statins: Examining Widely Used Drugs in the Aging Context**

This passage delves into the potential anti-aging effects of two commonly used drugs: metformin and statins. Metformin, traditionally prescribed for type II diabetes, has appeared as a candidate for modulating aging, with recent studies showcasing an approximately 5% increase in male mouse median and maximum lifespan [41]. Given its safety profile in human administration, metformin is notably considered a dietary restriction mimetic, activating AMP kinase in response to cellular energy deficits [42]. The drug's positive impact extends to age-related diseases, lowering the risk of heart-related disease and cancer, as suggested by clinical studies [43, 44]. The discussion on statins explores their inhibition of HMG-CoA reductase, leading to reduced LDL-associated cholesterol levels [45, 46]. While simvastatin did not show longevity benefits in the NIA Intervention Testing Program, statins have demonstrated protective effects against age-related diseases, including dementia and certain cancers, in human clinical trials [47]. However, caution is advised due to manageable side effects in some patients, inconsistent protective effects in clinical studies, and debates about the efficacy of statins for cardiovascular disease in individuals over 80. The passage emphasizes the need for further studies before conclusively categorizing statins as anti-aging drugs.

### **CONCLUSION**

In conclusion, the exploration of vitality and aging mechanisms has witnessed remarkable strides in recent research. From the identification of the Methuselah gene, offering potential for robust aging, to the genomic and transcriptomic insights into the biological immortality of *T. dohrnii*, the pursuit of understanding aging has taken intriguing directions. The evolutionary dynamics of aging, shaped by natural selection and adapting to factors such as cellular aging, have been uncovered through diverse models, including invertebrates and cnidarians.

The discussion on small molecules like rapamycin and resveratrol has unveiled promising possibilities for extending lifespan, with rapamycin demonstrating notable longevity benefits in mouse studies. Sirtuins, particularly SIRT1 and SIRT6, have been involved in

longevity pathways across species, showcasing the complexity of their roles in aging. Additionally, widely used drugs like metformin and statins have emerged as potential modulators of aging, with metformin showing positive effects on mouse lifespan.

As the quest to decipher the molecular intricacies of aging continues, the integration of findings into pharmaceutical interventions becomes a crucial focus. The potential to postpone human aging through small molecules or established drugs opens new avenues for anti-aging strategies. However, challenges such as regulatory hurdles, the gradual nature of aging, and uncertainties post-disease onset pose complex questions for the practical implementation of anti-aging drugs in healthcare. In this dynamic landscape of aging research, further studies are essential to validate and refine the potential interventions. The complex interaction between genetic, molecular, and environmental factors necessitates a comprehensive understanding to develop effective and safe approaches for extending health span. The journey from Methuselah to modern genomic exploration signals a promising era for aging research, with the potential to transform how we perceive and address the challenges of a growing elderly demographic.

**Conflict of interests:** Declare None.

#### ACKNOWLEDGMENT

The authors are thankful to the technical assistant Mr. Ashim Dhar for his assistance in technical work.

#### REFERENCES

- Lin YJ, Seroude L, Benzer S, 1998. Extended life-span and stress resistance in the *Drosophila* mutant methuselah. *Science* (New York, N.Y.). 282, Pages- 943-946. PMID 9794765 Doi: 10.1126/Science.282.5390.943.
- Flatt T, Schmidt PS, 2009. Integrating evolutionary and molecular genetics of aging. *Biochimica ET Biophysica Acta*. 1790: Pages - 951–962. 10.1016/j.bbagen.2009.07.010.
- López-Otín C, Kroemer G, 2021. Hallmarks of health. *Cell*, Pages-184: 1929–1939. 10.1016/j.cell.2020.11.034.
- López-Otín C, Blasco MA, Partridge L et.al, 2013. The hallmarks of aging. *Cell*. 153, Pages - 1194–1217. 10.1016/ j.cell.2013.05.039.
- Putnam NH, Srivastava M, Hellsten U, et.al, 2007. Sea anemone genome reveals ancestral eumetazoan gene repertoire and genomic organization. *Science* (New York, N.Y.). 317(5834), Pages- 86–94. Doi: <https://doi.org/10.1126/science.1139158>.
- Chapman J, Kirkness E, Simakov O, et al, 2010. The dynamic genome of *Hydra*. *Nature*. 464: Pages- 592–596. Doi: <https://doi.org/10.1038/nature08830>.
- Gold DA, Katsuki T, Li Y, et.al, 2019. The genome of the jellyfish *Aurelia* and the evolution of animal complexity. *Nature Ecology & Evolution*. 3, Pages- 96–104. Doi: <https://doi.org/10.1038/s41559-018-0719-8>.
- De Vito D, Piraino S, Schmich J, et al, 2006. Evidence of reverse development in Leptomedusae (Cnidaria, Hydrozoa): The case of *Laodicea undulata* (Forbes and Goodsir 1851). *Marine Biology*. 149, Pages- 339–346. Doi: 10.1007/s00227-005-0182-3.
- Schmid V, Wydler M, Alder H, 1982. Transdifferentiation and regeneration in vitro. *Dev. Biol.* 92, Pages- 476–488. Doi: 10.1016/0012-1606(82)90193-2.
- Li JY, Guo DH, Wu PC, et al, 2018. Ontogeny reversal and phylogenetic analysis of *Turritopsis* sp.5 (Cnidaria, Hydrozoa, Oceaniiidae), a possible new species endemic to Xiamen. *China. PeerJ*. 6, e4225. 10.7717/peerj.4225.
- Pascual-Torner M, Carrero D, Pérez-Silva JG, et al, 2022. Comparative genomics of mortal and immortal cnidarians unveils novel keys behind rejuvenation. *Proc. Natl. Acad. Sci. USA*. 119, e2118763119. 10.1073/pnas.2118763119.
- Umeda-Kameyama Y, Tsuda M, Ohkura C, et al, 2007. Thioredoxin suppresses Parkin-associated endothelin receptor-like receptor-induced neurotoxicity and extends longevity in *Drosophila*. *The Journal of biological chemistry*. 282(15), Pages- 11180–11187. Doi: <https://doi.org/10.1074/jbc.M700937200>.
- Ojimi MC, Isomura N, Hidaka M, 2009. Telomerase activity is not related to life history stage in the jellyfish *Cassiopea* sp. *Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology*. 152, Pages- 240–244. Doi: <https://doi.org/10.1016/j.cbpa.2008.10.008>.
- Storz JF, 2016. Causes of molecular convergence and parallelism in protein evolution. *Nature Reviews genetics*. 17, Pages- 239–250. Doi: <https://doi.org/10.1038/nrg.2016.11>.
- Watanabe H, Fujisawa T, Holstein TW, 2009. Cnidarians and the evolutionary origin of the nervous system. *Development, Growth and Differentiation*. 51, Pages- 167–183. Doi: <https://doi.org/10.1111/j.1440-169X.2009.01103.x>
- Chera S, Ghila L, Dobretz K, et al, 2009. Apoptotic cells provide an unexpected source of Wnt3 signaling to drive hydra head regeneration. *Developmental cell*. 17(2), Pages- 279–289. Doi: <https://doi.org/10.1016/j.devcel.2009.07.014>
- Segkilia A, Seuntjens E, Elkouris M, et al, 2012. *Bmp7* regulates the survival, proliferation, and neurogenic properties of neural progenitor cells during corticogenesis in the mouse. *PloS one*. 7(3), e34088. Doi: <https://doi.org/10.1371/journal.pone.0034088>
- Bollum LK, Huse K, Oksvold MP, et al, 2017. BMP-7 induces apoptosis in human germinal center B cells and is influenced by TGF- $\beta$  receptor type I ALK5. *PloS one*. 12(5), e0177188. Doi: <https://doi.org/10.1371/journal.pone.0177188>.
- Fogarty CE, Bergmann A, 2017. Killers creating new life: Caspases drive apoptosis-induced proliferation in tissue repair and disease. *Cell Death Differentiation*. 24, Pages- 1390–1400. Doi: <https://doi.org/10.1038/cdd.2017.47>.
- Rosendorff A, Sakakibara S, Lu S, et al, 2006. NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. *Proceedings of the National Academy of Sciences of the United States of America*. 103(14) Pages- 5308–5313. Doi: <https://doi.org/10.1073/pnas.0601066103>
- Ma L, Prada AM, Schmidt M, et al, 2021. Generation of pathogenic TPP1 mutations in human stem cells as a model for

- neuronal ceroid lipofuscinosis type 2 disease. *Stem Cell Research (Amst.)*. 53, 102323. Doi: <https://doi.org/10.1016/j.scr.2021.102323>.
22. Takahashi K, Yamanaka S, 2016. A decade of transcription factor-mediated reprogramming to pluripotency. *Nature Reviews Molecular Cell Biology*. 17, Pages- 183–193. Doi: <https://doi.org/10.1038/nrm.2016.8>.
  23. Girirajan S, Hauck PM, Williams S, et al, 2008. Tom112 hypomorphic mice exhibit increased incidence of infections and tumors and abnormal immunologic response. *Mammalian Genome*. 19, Pages- 246–262. Doi: <https://doi.org/10.1007/s00335-008-9100-6>.
  24. Jager M, Queinnee E, Le Guyader H, et al, 2011, Multiple Sox genes are expressed in stem cells or in differentiating neurosensory cells in the hydrozoan *Clytia hemisphaerica*. *Evodevo*. 2, 12. Doi: <https://doi.org/10.1186/2041-9139-2-12>.
  25. Hartl M, Mitterstiller AM, Valovka T, et al, 2010. Stem cell-specific activation of an ancestral myc protooncogene with conserved basic functions in the early metazoan Hydra. *Proceedings of the National Academy of Sciences of the United States of America*. 107 (9), Pages - 4051–4056. Doi: <https://doi.org/10.1073/pnas.0911060107>.
  26. Vezina C, Kudelski A, Sehgal SN, et al, 1975. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. *J Antibiot (Tokyo)*. 28(10), Pages- 721–6. Doi: <https://doi.org/10.7164/antibiotics.28.721>.
  27. Stanfel MN, Shamieh LS, Kaerberlein M, et al 2009. The TOR pathway comes of age. *Biochim Biophys Acta*. 1790(10), Pages- 1067–74. Doi: <https://doi.org/10.1016/j.bbagen.2009.06.007>.
  28. Lamming DW, Ye L, Sabatini DM, et al 2013. Rapalogs and mTOR inhibitors as anti-aging therapeutics. *J Clin Invest*. 123(3), Pages- 980–9. Doi: <https://doi.org/10.1172/JCI64099>.
  29. Johnson SC, Rabinovitch PS, Kaerberlein M, et al 2013. mTOR is a key modulator of ageing and age-related disease. *Nature*. 493(7432), Pages- 338–45. Doi: <https://doi.org/10.1038/nature11861>.
  30. Laplante M, Sabatini DM, 2012. mTOR signaling in growth control and disease. *Cell*. 149(2), Pages- 274–93. Doi: <https://doi.org/10.1016/j.cell.2012.03.017>.
  31. Harrison DE, Strong R, Sharp ZD, et al 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature*. 460(7253), Pages- 392–5. Doi: <https://doi.org/10.1038/nature08221>.
  32. Flynn JM, O'Leary MN, Zambataro CA, et al 2013. Late life rapamycin treatment reverses age-related heart dysfunction. *Aging Cell*. 12(5), Pages- 851–862. Doi: <https://doi.org/10.1111/acel.12109>.
  33. Malagelada C, Jin ZH, Jackson-Lewis V, et al 2010. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. *J Neurosci*. 30(3), Pages- 1166–75. Doi: <https://doi.org/10.1523/JNEUROSCI.3944-09.2010>.
  34. Kaerberlein M, McVey M, Guarente L, et al 1999. The SIR2/3/4 complex and SIR2 alone promote longevity in *Saccharomyces cerevisiae* by two different mechanisms. *Genes Dev*. 13, Pages- 2570–80. <https://doi.org/10.1101/gad.13.19.2570>.
  35. Sinclair DA, Guarente L, 1997. Extrachromosomal rDNA circles—a cause of aging in yeast. *Cell*. 91, Pages-1033–42. Doi: [https://doi.org/10.1016/S0092-8674\(00\)80493-6](https://doi.org/10.1016/S0092-8674(00)80493-6).
  36. Satoh A, Brace CS, Rensing N, et al 2013. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. *Cell Metab*. 18, Pages- 416–30. Doi: <http://dx.doi.org/10.1016/j.cmet.2013.07.013>.
  37. Howitz KT, Bitterman KJ, Cohen HY, et al 2003. Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature*. 425, Pages- 191–6. Doi: <https://doi.org/10.1038/nature01960>.
  38. Hall JA, Dominy JE, Lee Y, et al 2013. The sirtuin family's role in aging and age-associated pathologies. *J Clin Invest*. 123(3), Pages- 973–9. Doi: <https://doi.org/10.1172/JCI64094>.
  39. Kaerberlein M, Mc Donagh T, Heltweg B, et al, 2005. Substrate specific activation of sirtuins by resveratrol. *J Biol Chem*. 280, Pages-17038–45. Doi: <https://doi.org/10.1074/jbc.M500655200>.
  40. Borra MT, Smith BC, Denu JM, et al 2005. Mechanism of human SIRT1 activation by resveratrol. *J Biol Chem*. 280(17), Pages- 17187–95. Doi: <https://doi.org/10.1074/jbc.M501250200>.
  41. Martin-Montalvo A, Mercken EM, Mitchell SJ, et al 2013. Metformin improves healthspan and lifespan in mice. *Nat Commun*. 4, Pages-2192. Doi: <https://doi.org/10.1038/ncomms3192>.
  42. Hardie DG, Ross FA, Hawley SA, et al 2012. AMP-activated protein kinase: a target for drugs both ancient and modern. *Chem Biol*. 19(10), Pages-1222–36. Doi: <https://doi.org/10.1038/ncomms3192>.
  43. Pollak MN, 2012. Investigating metformin for cancer prevention and treatment: the end of the beginning. *Cancer Discov*. 2(9), Pages- 778–90. Doi: <https://doi.org/10.1158/2159-8290.CD-12-0263>.
  44. Ovalle F, 2011. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. *Clin Ther*. 33(4), Pages- 393–407. Doi: <https://doi.org/10.1016/j.clinthera.2011.04.006>.
  45. Schiattarella GG, Perrino C, Magliulo F, et al 2012. Statins and the elderly: recent evidence and current indications. *Aging Clin Exp Res*. 24(3 Suppl), Pages- 47–55.
  46. Kolovou G, Kolovou V, Vasiliadis I, et al 2011. Ideal lipid profile and genes for an extended life span. *Curr Opin Cardiol*. 26(4), Pages- 348–55. Doi: <https://doi.org/10.1097/HCO.0b013e32834659d4>.
  47. Miller RA, Harrison DE, Astle CM, et al 2011. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. *J Gerontol A Biol Sci Med Sci*. 66(2), Pages- 191–201. Doi: <https://doi.org/10.1093/gerona/gdq178>.